Media headlines about Bioanalytical Systems (NASDAQ:BASI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.0729388167031 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Bioanalytical Systems (NASDAQ BASI) opened at 1.80 on Wednesday. Bioanalytical Systems has a 1-year low of $0.60 and a 1-year high of $2.42. The firm’s market capitalization is $14.74 million. The company has a 50-day moving average price of $1.75 and a 200 day moving average price of $1.44.

Bioanalytical Systems (NASDAQ:BASI) last posted its earnings results on Monday, May 15th. The company reported $0.05 EPS for the quarter. The company had revenue of $6.36 million for the quarter. Bioanalytical Systems had a negative return on equity of 29.32% and a negative net margin of 8.95%. Analysts expect that Bioanalytical Systems will post $0.01 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Bioanalytical Systems (NASDAQ:BASI) Earns Daily News Sentiment Rating of 0.17” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at

Bioanalytical Systems Company Profile

Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems Inc. and related companies with's FREE daily email newsletter.